In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) gapped down before the market opened on Friday .The stock had previously closed at $28.17, but opened at $27.00. Galapagos shares last traded at $26. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on Galapagos (0JXZ – Research Report), with a price target of ...

Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”), today announced a planned separation into two entities: a newly to be formed company (to be named at a later date, herein “SpinCo ...

U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a ...

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco ...

Hedge funds and other institutional investors own 32.46% of the company’s stock. Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the ...

MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”), today announced a planned ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...